influenza
sentinel
clinic
nonsentinel
institut
send
origin
sampl
local
public
health
laboratori
detect
viru
isol
total
clinic
specimen
compris
origin
sampl
n
clinic
isol
n
underw
either
full
partial
nt
na
sequenc
detect
mutat
sampl
case
collect
oseltamivir
exposur
associ
oseltamivir
use
associ
zanamivir
use
antiviru
treatment
statu
unknown
collect
pandem
isol
randomli
select
os
isol
local
public
health
laboratori
repres
os
pandem
isol
underw
na
inhibit
assay
os
virus
test
full
na
hemagglutin
ha
sequenc
os
intern
gene
sequenc
os
hemagglutin
inhibit
hi
test
os
phylogenet
tree
na
ha
gene
construct
neighborjoin
method
phylogenet
tree
construct
use
repres
os
pandem
isol
sever
prefectur
japan
sequenc
inform
pandem
countri
download
global
initi
share
avian
influenza
data
gisaid
genbank
amino
acid
posit
phylogenet
tree
describ
number
chemiluminesc
nai
assay
perform
nastar
kit
appli
biosystem
tokyo
japan
briefli
final
drug
concentr
nm
oseltamivir
nm
zanamivir
chemiluminesc
assay
plate
reader
berthhold
technolog
bad
wilbad
germani
drug
concentr
requir
inhibitori
concentr
na
activ
calcul
mikrowin
softwar
ver
mikrotek
laborsystem
gmbh
overath
germani
valid
nai
assay
use
alreadi
character
drugresist
virus
sensit
counterpart
control
zanamivir
oseltamivir
boxandwhisk
plot
use
determin
cutoff
valu
nairesist
outlier
sensit
virus
box
contain
result
repres
middl
quartil
length
box
show
interquartil
rang
iqr
cutoff
valu
defin
upper
quartil
interquartil
rang
percentil
statist
analys
pandem
virus
mutat
exclud
overal
popul
hi
test
perform
evalu
reactiv
ferret
antiserum
vaccin
strain
describ
manual
efficaci
ferret
postinfect
antiserum
egggrown
use
refer
antiserum
treat
receptordestroy
enzym
ii
denka
seiken
tokyo
japan
adsorb
turkey
erythrocyt
test
prevent
nonspecif
reaction
suspens
turkey
erythrocyt
use
hi
test
clinic
specimen
isol
may
collect
prefectur
japan
mutat
detect
na
sequenc
total
pandem
virus
possess
n
mix
n
mutat
figur
pandem
emerg
sporad
sever
prefectur
detect
period
sever
month
figur
figur
casepati
oseltamivir
treatment
zanamivir
treatment
naiuntreat
treatment
histori
unknown
case
pandem
associ
oseltamivir
treatment
postexposur
prophylaxi
occur
naiuntreat
patient
thu
oseltamivir
treatment
prophylaxi
like
acceler
emerg
pandem
relationship
time
sampl
day
oseltamivir
treatment
pandem
detect
show
pandem
gener
detect
least
day
oseltamivir
treatment
tabl
casepati
male
year
year
year
year
underli
medic
condit
known
chronic
underli
medic
condit
pulmonari
neurolog
blood
diabet
kidney
diseas
immunocompromis
condit
almost
pandem
case
emerg
sporad
epidemiolog
link
howev
case
humantohuman
transmiss
suspect
one
observ
niigata
prefectur
children
hospit
room
infect
pandem
viru
within
day
symptom
develop
first
girl
octob
receiv
oseltamivir
pandem
viru
isol
patient
octob
boy
room
receiv
prophylaxi
treatment
dosag
oseltamivir
begin
octob
howev
experienc
symptom
octob
pandem
viru
isol
octob
patient
doubl
room
patient
pandem
around
genet
analys
virus
ie
show
aa
differ
g
posit
also
share
uniqu
chang
tabl
transmiss
possibl
follow
pandem
directli
transmit
femal
patient
os
pandem
transmit
femal
patient
pandem
viru
emerg
male
patient
suspect
instanc
humantohuman
transmiss
occur
tottori
prefectur
boy
symptom
develop
decemb
pandem
viru
isol
sampl
collect
day
oseltamivir
use
howev
patient
brother
infect
pandem
viru
receiv
oseltamivir
sinc
decemb
although
sampl
person
avail
pandem
like
emerg
patient
transmit
detail
epidemiolog
inform
avail
person
pandem
infect
untreat
nai
besid
case
tottori
prefectur
anoth
occur
oita
prefectur
index
patient
mild
cough
begin
juli
typic
influenza
symptom
develop
juli
pandem
viru
detect
sampl
taken
juli
oseltamivir
use
howev
symptom
develop
index
patient
son
juli
boy
receiv
zanamivir
juli
pandem
viru
detect
sampl
taken
day
report
indic
zanamivir
induc
viru
mutat
pandem
viru
may
thu
emerg
natur
select
pressur
howev
index
patient
may
expos
oseltamivirtr
person
outsid
household
harbor
pandem
viru
phylogenet
analys
ha
na
gene
show
share
amino
acid
chang
ha
na
figur
tree
pandem
isol
genet
scatter
possess
sever
sporad
amino
acid
chang
pandem
genet
close
os
pandem
figur
sever
pandem
isol
japan
also
close
relat
pandem
isol
countri
analysi
genom
repres
n
os
pandem
n
provid
insight
similar
first
comparison
intern
amino
acid
sequenc
pandem
os
pandem
isol
consensu
show
virus
possess
sever
sporad
amino
acid
chang
exhibit
common
amino
acid
chang
uniqu
pandem
virus
indic
intern
gene
os
pandem
virus
genet
indistinguish
tabl
second
comparison
sampl
patient
pandem
oseltamivir
treatment
show
chang
na
chang
protein
final
evid
reassort
pandem
season
influenza
virus
detect
pandem
isol
patient
mix
na
gene
popul
patient
receiv
oseltamivir
sampl
would
collect
select
gener
pandem
os
pandem
figur
calcul
precis
valu
mix
popul
nairesist
sensit
virus
possibl
mix
isol
exclud
overal
popul
purpos
statist
analysi
nai
data
summar
tabl
averag
valu
pandem
n
oseltamivir
higher
os
pandem
n
virus
zanamivir
virus
identifi
outlier
cutoff
nm
compar
consensu
sequenc
os
pandem
one
os
pandem
nm
mixtur
na
protein
pandem
nm
nm
possess
substitut
na
protein
respect
tabl
valu
os
pandem
virus
similar
season
influenza
counterpart
virus
tabl
suscept
inhibitor
determin
sequenc
test
virus
includ
n
os
pandem
n
resist
marker
protein
suggest
pandem
isol
resist
inhibitor
hi
test
perform
estim
reactiv
os
n
pandem
n
viru
ferret
antiserum
vaccin
strain
os
n
pandem
n
isol
inhibit
ferret
antiserum
os
n
pandem
n
respect
show
reduc
hi
titer
os
n
pandem
n
either
chang
deduc
antigen
site
ha
protein
show
least
reduct
hi
titer
thu
os
pandem
antigen
indistinguish
similar
current
vaccin
strain
data
present
provid
evid
sustain
spread
pandem
japan
studi
clinic
specimen
collect
naiuntreat
naitreat
patient
later
sampl
collect
exert
select
pressur
drug
treatment
howev
frequenc
detect
pandem
low
os
pandem
isol
genet
antigen
indistinguish
current
vaccin
would
expect
effect
recent
pandem
evid
reassort
season
influenza
viru
detect
immunocompet
patient
infect
pandem
show
typic
uncompl
influenza
symptom
similar
caus
os
pandem
earli
report
suggest
worldwid
consumpt
oseltamivir
occur
japan
longterm
nai
surveil
japan
previou
nai
surveil
show
low
frequenc
resist
virus
suggest
transmiss
virus
select
drug
pressur
remark
reduc
howev
begin
novemb
unexpectedli
high
frequenc
season
influenza
virus
mutat
detect
europ
isol
naiuntreat
patient
transmiss
os
influenza
result
rapid
global
dissemin
contrast
even
season
influenza
detect
rare
japan
despit
high
level
oseltamivir
use
howev
influenza
viru
detect
far
higher
frequenc
next
year
thu
pattern
oseltamivir
use
correspond
emerg
widespread
distribut
influenza
virus
contrast
studi
recent
report
found
pandem
detect
predominantli
isol
oseltamivir
recipi
unlik
recent
influenza
virus
pandem
virus
seem
restrict
transmiss
among
human
find
indic
oseltamivir
use
respons
emerg
pandem
virus
perhap
widespread
distribut
pandem
although
reason
recent
season
influenza
isol
lose
fit
remain
unclear
function
defect
na
protein
caus
may
counteract
permiss
secondari
mutat
two
mutat
identifi
season
influenza
although
whether
amino
acid
correspond
posit
pandem
play
similar
role
unknown
na
protein
viru
v
residu
posit
respect
v
posit
ident
nonpermiss
amino
acid
sequenc
sporad
share
amino
acid
chang
observ
na
protein
pandem
virus
chang
appar
restor
viral
fit
effici
transmiss
pandem
viru
found
observ
suggest
na
protein
recent
pandem
isol
like
possess
permiss
secondari
mutat
tabl
howev
recent
anim
studi
pandem
viru
shown
viral
fit
transmiss
differ
os
pandem
viru
potenti
supersed
os
pandem
viru
nevertheless
pandem
supersed
os
pandem
human
inconsist
may
explain
differ
infecti
dose
use
anim
model
nai
assay
zanamivir
suscept
statist
analysi
identifi
outlier
one
os
pandem
possess
mutat
report
affect
suscept
zanamivir
season
virus
two
pandem
isol
substitut
na
howev
whether
affect
zanamivir
suscept
unclear
also
assay
peramivir
suscept
repres
os
pandem
isol
data
suggest
pandem
viru
contain
substitut
possess
crossresist
peramivir
report
anoth
group
case
report
preliminari
nai
surveil
indic
group
high
risk
gener
resist
virus
first
patient
sever
compromis
suppress
immun
system
shed
viru
prolong
period
thu
increas
chanc
develop
resist
viru
report
resist
case
april
occur
immunocompromis
patient
second
group
person
receiv
postexposur
prophylaxi
take
subtherapeut
dose
mg
treatment
dosag
mg
regimen
may
partial
inhibit
viral
replic
thu
facilit
emerg
pandem
recommend
chemoprophylaxi
person
higher
risk
sever
complic
ill
group
observ
studi
found
pandem
viru
detect
sampl
collect
least
day
oseltamivir
treatment
prophylaxi
tabl
howev
frequenc
pandem
day
treatment
oseltamivir
could
calcul
lack
treatment
histori
data
time
consist
season
influenza
pandem
virus
typic
emerg
day
oseltamivir
treatment
addit
also
observ
rapid
emerg
pandem
viru
within
hour
oseltamivir
exposur
nontheless
case
occur
untreat
patient
inde
pandem
oita
case
may
like
natur
occurr
awar
report
one
vietnam
one
hong
kong
natur
occur
pandem
untreat
patient
greatest
concern
regard
pandem
drugresist
virus
acquir
abil
transmit
effici
among
human
recent
season
influenza
two
hospit
outbreak
unit
kingdom
unit
state
report
immun
system
patient
sever
compromis
suppress
indic
patient
increas
risk
emerg
pandem
viru
also
season
influenza
viru
contrast
particular
attent
paid
vietnames
case
natur
occur
pandem
viru
caus
cluster
case
immunocompet
patient
histori
oseltamivir
use
despit
high
level
oseltamivir
use
japan
preval
pandem
remain
low
thu
oseltamivir
remain
first
option
treat
pandem
zanamivir
consid
immunocompromis
patient
addit
first
prioriti
prophylaxi
os
pandem
infect
vaccin
antivir
agent
convers
preclin
anim
model
show
pandem
high
potenti
acquir
transmiss
without
lose
viral
fit
whether
pandem
may
acquir
effici
transmiss
among
human
known
thu
vigil
monitor
pandem
infect
alter
transmiss
antigen
genet
characterist
essenti
member
influenza
viru
surveil
group
japan
hideki
nagano
hokkaido
institut
public
health
masayuki
kikuchi
sapporo
citi
institut
public
health
masaki
takahashi
research
institut
environment
scienc
public
health
iwat
prefectur
yuki
sato
miyagi
prefectur
institut
public
health
environ
masanori
katsumi
sendai
citi
institut
public
health
hiroyuki
saito
akita
research
center
public
health
environ
katsumi
mizuta
yamagata
prefectur
institut
public
health
syoko
hiros
fukushima
prefectur
institut
public
health
setsuko
fukaya
ibaraki
prefectur
institut
public
health
teruko
oogan
tochigi
prefectur
institut
public
health
environment
scienc
hiroyuki
tsukagoshi
gunma
prefectur
institut
public
health
environment
scienc
yuka
uno
saitama
citi
institut
health
scienc
research
hiromi
maru
chiba
prefectur
institut
public
health
hajim
yokoi
chiba
citi
institut
health
environ
mami
nagashima
tokyo
metropolitan
institut
public
health
sumi
watanab
kanagawa
prefectur
institut
public
health
hideaki
shimizu
kawasaki
citi
institut
public
health
sumiko
ueda
sagamihara
citi
laboratori
public
health
miyako
kon
niigata
prefectur
institut
public
health
environment
scienc
gen
kobayashi
yoko
miyajima
niigata
citi
institut
public
health
environ
sana
kuramoto
ishikawa
prefectur
institut
public
health
environment
scienc
masako
nakamura
fukui
prefectur
institut
public
health
hiroyoshi
asakawa
yamanashi
institut
public
health
seiko
sawatari
gifu
prefectur
institut
health
enviroment
scienc
yasunori
tanaka
gifu
municip
institut
public
health
toshihiro
yamada
shizuoka
institut
environ
hygien
shinobu
ide
shizuoka
citi
institut
environment
scienc
public
health
yoshinori
kohno
hamamatsu
citi
health
environ
research
center
yoshihiro
yasui
aichi
prefectur
institut
public
health
noriko
goto
nagoya
citi
public
health
research
institut
takuya
yano
mie
prefectur
health
environ
research
institut
fumi
matsumoto
shiga
prefectur
institut
public
health
tohru
ishizaki
kyoto
prefectur
institut
public
health
environ
satoshi
hiroi
osaka
prefectur
institut
public
health
hideyuki
kubo
osaka
citi
institut
public
health
environment
scienc
kiyoko
uchino
sakai
citi
institut
public
health
tomohiro
oshib
hyogo
prefectur
institut
public
health
consum
scienc
ai
mori
kobe
institut
health
yoshiteru
kitahori
nara
prefectur
institut
hygien
environ
fumio
terasoma
wakayama
prefectur
research
center
environ
public
health
takayuki
hirooka
hidenobu
egawa
wakayama
citi
institut
public
health
yoshiaki
kimura
tottori
prefectur
institut
public
health
environment
scienc
tamaki
omura
shiman
prefectur
institut
public
health
environment
scienc
shinichi
takao
center
public
health
environ
hiroshima
prefectur
technolog
research
institut
katsuhiko
abe
hiroshima
citi
institut
public
health
yumiko
kawakami
tokushima
prefectur
centr
public
health
environment
scienc
satomi
aoki
ehim
prefectur
institut
public
health
environment
scienc
daisuk
kawamoto
fukuoka
citi
institut
hygien
environ
takayuki
hirano
saga
prefectur
institut
public
health
pharmaceut
research
manabu
hirano
nagasaki
prefectur
institut
environ
research
public
health
seiya
harada
kumamoto
prefectur
institut
publichealth
environment
scienc
miki
kato
oita
prefectur
institut
health
environ
miho
miura
miyazaki
prefectur
institut
public
health
environ
kanji
ishitani
kagoshima
prefectur
institut
environment
research
pubul
health
katsuya
taira
okinawa
prefectur
institut
health
environ
mitsutaka
kuzuya
okayama
prefectur
institut
environment
scienc
public
health
shoichi
toda
yamaguchi
prefectur
institut
public
health
environ
chiharu
kawakami
yokohama
citi
institut
health
mayumi
konno
kyoto
citi
institut
health
environment
scienc
hiroya
komoda
kagawa
prefectur
research
institut
environment
scienc
public
health
tae
taniwaki
kochi
public
health
sanit
institut
toshitaka
minegishi
saitama
institut
pubul
health
rika
tsutsui
aomori
prefectur
institut
public
health
environ
shizuko
kasuo
nagano
environment
conserv
research
institut
yuichiro
okamura
nagano
citi
health
center
eiji
horimoto
toyama
institut
health
nobuyuki
sera
fukuoka
institut
health
environment
scienc
kotaro
muras
kitakyushu
citi
institut
environment
scienc
